Bergen's new president is ex-Pracon head Roden: capitation pioneer returns after 20 years.
BERGEN BRINGS BACK RODEN: "RESPECTED RELATIONSHIPS with leaders of the manufacturing and professional communities" form one of the prime attractions behind the choice of Donald Roden as president and CEO of the $8.5 bil. wholesaler/medical product supplier. During an early phase of his 25-year career in the pharmaceutical industry, Roden was part of a business development group at Bergen that experimented with running state Medicaid programs on an at-risk basis. Roden, 49, was with Bergen from 1974 to 1977 and served as a group VP for the subsidiary that ran the state contracts, Health Application Systems.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth